Determination of celecoxib, a COX-2 inhibitor, in pharmaceutical dosage forms by MEKC

A micellar electrokinetic chromatographic (MEKC) method was developed for the quantification of celecoxib, a COX-2 inhibitor in pharmaceutical dosage forms within the total analysis time of 7 min. The method has been validated and proven to be rugged. The quantification was carried out at 35 degrees C and 25 kV, using a 25 mM borate buffer (pH 9.3), 25 mM sodium dodecyl sulphate with an extended light path capillary (48.5 cm x 50 micro I.D., 40 cm to detector). Calibration curves were constructed for celecoxib (0.2-0.6 mg/ml) by the internal standard method with 2-nitro aniline as an internal standard (coefficient of correlation greater than 0.999). The intermediate precision (between day precision) of migration times and peak area ratios of celecoxib to internal standard were 1.44 and 1.58% R.S.D., demonstrates good reproducibility of the method. The method was applied to a commercial celecoxib formulation (Revibra, 100 mg) and the percentage recoveries were ranged from 93.0 to 98.4%.